UCARTMUC1 / Cellectis - LARVOL DELTA

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety (GlobeNewswire) - "Cellectis...published a scientific article in Science Advances suggesting that TALEN-edited MUC1 CAR T-cells could be a potential treatment option for advance-stage triple negative breast cancer (TNBC) patients with limited therapeutic options....Cellectis demonstrates enhanced cytotoxic activity of MUC1 CAR T-cells armored with PD1KO, tumor-specific IL12 release and TGFBR2KO attributes, all of them catered towards the TNBC TME, in intravenous and intratumoral mouse models....Importantly, intratumoral treatment effectively reduced local and distant tumors of large size using low doses of multi-armored MUC1 CAR T-cells."

Preclinical • Triple Negative Breast Cancer

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) - "Cellectis...announced today that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego (CA)....The poster is number 254 and it is entitled 'TGF-Beta Blockade Combined with Activation-Induced IL12 Secretion Synergize to Optimize Potency of MUC1-CAR T-cells in Preclinical Targeting of Triple-Negative Breast Cancer'....'We demonstrate that combination of the ΔPD1-IL12 with TGFBR2 KO not only enhanced CAR-T cell activity but surprisingly limit their accumulation outside the tumor, therefore reducing the risks of off-tumor toxicity'."

Preclinical • Triple Negative Breast Cancer

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) - "Cellectis...announced today that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego (CA)."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Cellectis Presents Preclinical Data on TALEN-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "Cellectis...released preclinical data on TALEN®-edited MUC1 CAR T-cells at the American Association for Cancer Research (AACR) Annual Meeting 2023. The data showed the capability of armored allogeneic MUC1 CAR T-cells to excel in the immune suppressive tumor micro-environment suggesting that they could be an effective option in treating relapsed and refractory triple negative breast cancer (TNBC) patients with limited therapeutic options....Results demonstrate superior activity of armored MUC1-CAR T-cells not only in tumor clearance but also in the recovery of normal glands. Thus, innovative strategies can be used to allow CAR T-cell efficiency in the hostile tumor microenvironment while preserving safety."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Cellectis Announces Poster Presentation on TALEN-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "Cellectis...announced that preclinical data exploring purposeful armoring of CAR T-cells to enhance efficacy of MUC1 CAR T-cells in targeting triple-negative breast cancer, will be presented at the American Association of Cancer Research (AACR) Annual Meeting, to be held in Orlando, Florida on April 14-19, 2023."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022 (GlobeNewswire) - "TALEN®-edited smart CAR T-cells: On October 5, Cellectis announced that preclinical data on TALEN®-edited smart CAR T-cells supporting improved solid tumor targeting will be presented at the Society for Immunotherapy of Cancer’s (SITC) Annual meeting, to be held on November 8-12, 2022 in Boston. Cellectis will present two posters: (i) A poster on TALEN®-edited smart CAR T-cells targeting MUC1-expressing solid tumors; (ii) A poster on innovative T-cell engineering strategies designed to increase the activity of CAR T-cells for solid tumors while mitigating toxicity risks."

Preclinical • Oncology • Solid Tumor

Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities (GlobeNewswire) - "Cellectis outlines four new UCART preclinical programs, targeting solid tumors: (i) UCARTMUC1 for Mucin 1-expressing epithelial cancers: Preclinical data indicates that UCARTMUC1 shows strong intratumoral expansion translating into promising preclinical anti-tumor activity in vivo; (ii) UCARTFAPtargeting Cancer Associated Fibroblasts (CAFs) in the tumor microenvironment: TCR knocked out to prevent GVHD and beta-2 microglobulin knocked out to provide resistance to the patient’s own T-cells."

Preclinical • Hematological Malignancies • Oncology